MA54087A - Sels cristallins d'un inhibiteur de la kallicréine plasmatique - Google Patents

Sels cristallins d'un inhibiteur de la kallicréine plasmatique

Info

Publication number
MA54087A
MA54087A MA054087A MA54087A MA54087A MA 54087 A MA54087 A MA 54087A MA 054087 A MA054087 A MA 054087A MA 54087 A MA54087 A MA 54087A MA 54087 A MA54087 A MA 54087A
Authority
MA
Morocco
Prior art keywords
kallicrein
inhibitor
plasma
crystalline salts
crystalline
Prior art date
Application number
MA054087A
Other languages
English (en)
Inventor
Yarlagadda S Babu
Yahya El-Kattan
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70457981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54087(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MA54087A publication Critical patent/MA54087A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA054087A 2018-11-02 2019-11-01 Sels cristallins d'un inhibiteur de la kallicréine plasmatique MA54087A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862754983P 2018-11-02 2018-11-02

Publications (1)

Publication Number Publication Date
MA54087A true MA54087A (fr) 2022-02-09

Family

ID=70457981

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054087A MA54087A (fr) 2018-11-02 2019-11-01 Sels cristallins d'un inhibiteur de la kallicréine plasmatique

Country Status (22)

Country Link
US (11) US10662160B1 (fr)
EP (1) EP3873463A4 (fr)
JP (2) JP2022505670A (fr)
KR (1) KR102810837B1 (fr)
CN (1) CN112969458A (fr)
AR (1) AR116951A1 (fr)
AU (1) AU2019374115B8 (fr)
BR (1) BR112021008249A2 (fr)
CA (1) CA3117123A1 (fr)
CL (1) CL2021001094A1 (fr)
CO (1) CO2021007172A2 (fr)
EA (1) EA202191192A1 (fr)
IL (2) IL322896A (fr)
MA (1) MA54087A (fr)
MX (1) MX2021004917A (fr)
PE (1) PE20211280A1 (fr)
PH (1) PH12021550883A1 (fr)
PY (1) PY1991831A (fr)
SG (1) SG11202103804TA (fr)
TW (1) TW202031255A (fr)
UY (1) UY38438A (fr)
WO (1) WO2020092898A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3113772T (lt) 2014-03-07 2020-12-28 Biocryst Pharmaceuticals, Inc. Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
WO2021025969A1 (fr) * 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Formes à l'état solide de bérotralstat
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
CA2589886A1 (fr) 2004-12-15 2006-06-22 Bristol-Myers Squibb Company Formes cristallines d'un inhibiteur de facteur xa
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
US9206146B2 (en) 2010-05-19 2015-12-08 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
KR20130105675A (ko) 2010-11-25 2013-09-25 라티오팜 게엠베하 아파티닙의 신규 염 및 다형
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
LT3113772T (lt) 2014-03-07 2020-12-28 Biocryst Pharmaceuticals, Inc. Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
PL3355890T3 (pl) 2015-10-01 2022-02-21 Biocryst Pharmaceuticals, Inc. Inhibitory ludzkiej kalikreiny osoczowej
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
EP4010320A4 (fr) 2019-08-06 2023-08-16 Biocryst Pharmaceuticals, Inc. Synthèse à l'échelle du processus d'un inhibiteur de la kallicréine plasmatique

Also Published As

Publication number Publication date
WO2020092898A1 (fr) 2020-05-07
EP3873463A1 (fr) 2021-09-08
PY1991831A (es) 2020-07-03
CO2021007172A2 (es) 2021-06-10
US20250388547A1 (en) 2025-12-25
AU2019374115B1 (en) 2025-07-17
US12552750B2 (en) 2026-02-17
US10662160B1 (en) 2020-05-26
BR112021008249A2 (pt) 2021-08-03
US12545646B2 (en) 2026-02-10
IL322896A (en) 2025-10-01
TW202031255A (zh) 2020-09-01
CN112969458A (zh) 2021-06-15
IL282454A (en) 2021-06-30
CL2021001094A1 (es) 2021-10-15
US11117867B2 (en) 2021-09-14
CA3117123A1 (fr) 2020-05-07
US20250388549A1 (en) 2025-12-25
US11618733B2 (en) 2023-04-04
MX2021004917A (es) 2021-06-18
UY38438A (es) 2020-05-29
AU2019374115B8 (en) 2025-08-07
JP2022505670A (ja) 2022-01-14
KR20210087037A (ko) 2021-07-09
US20250376448A1 (en) 2025-12-11
US12590069B2 (en) 2026-03-31
US12545647B2 (en) 2026-02-10
US20250388548A1 (en) 2025-12-25
US20250388545A1 (en) 2025-12-25
US20220204454A1 (en) 2022-06-30
US20200140389A1 (en) 2020-05-07
KR102810837B1 (ko) 2025-05-20
JP2024109860A (ja) 2024-08-14
EA202191192A1 (ru) 2021-09-23
AU2019374115A1 (en) 2021-06-03
US20250376447A1 (en) 2025-12-11
PE20211280A1 (es) 2021-07-19
US12590068B2 (en) 2026-03-31
US20240109844A1 (en) 2024-04-04
EP3873463A4 (fr) 2022-06-22
AR116951A1 (es) 2021-06-30
SG11202103804TA (en) 2021-05-28
US20200308118A1 (en) 2020-10-01
US20250388546A1 (en) 2025-12-25
US12545645B2 (en) 2026-02-10
PH12021550883A1 (en) 2022-02-21
US12344585B2 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
MA52493A (fr) Sels d'un inhibiteur de fgfr
EP3541807A4 (fr) Formes cristallines d'un inhibiteur de magl
IL290106A (en) Crystalline form of atr inhibitor and use thereof
MA42606A (fr) Sels d'un inhibiteur de lsd1
EP3807279A4 (fr) Sels pharmaceutiquement acceptables de sépiaptérine
EP3873463A4 (fr) Sels cristallins d'un inhibiteur de la kallicréine plasmatique
MA50223A (fr) Sels inhibiteurs de ferroportine
IL283860A (en) Crystalline forms and salt forms of a kinase inhibitor
IL287668A (en) Crystalline forms of a btk inhibitor
MA42780A (fr) Sels d'un inhibiteur de la kinase pim
EP3782987A4 (fr) Composé de benzo-pyrazole tenant lieu d'inhibiteur de la rho-kinase
MA56001A (fr) Formes de sel cristallin d'un inhibiteur de kinase
IL289929A (en) Crystal forms of cd73 inhibitor
DK3826982T3 (da) Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer
SG11202102110PA (en) Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor
EP3996707A4 (fr) Formes cristallines d'inhibiteurs de la kallicréine plasmatique
IL281168A (en) Crystal forms of the quinazole compound and its hydrochloride salts
EP3672972A4 (fr) Sels et formes cristallines d'un composé
HUE062106T2 (hu) Peptid-epoxiketon-immunoproteaszóma inhibitor kristályos sói
SI3891156T1 (sl) Nove kristalinične oblike tienopirimidina kot inhibitor Mcl-1
IL292847A (en) Crystalline forms of magl inhibitor
EP4045484A4 (fr) Sels d'un composé et leurs formes cristallines
EP3380481A4 (fr) Formes cristallines de sels de chlorhydrate d'un composé de thiénopyrimidine
HK40057799A (zh) 血浆激肽释放酶抑制剂的结晶盐
DK3898638T3 (da) Krystallinske former af en par4-hæmmer